Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.
Tom Robinson, vice president of global access at JDRF, goes over what policies are needed to implement and ensure access to 4 key type 1 diabetes (T1D) interventions: timely diagnosis, insulin and strips, pumps and continuous glucose monitors, and prevention and cures.
Transcript
What national or international policies are needed to ensure these interventions are implemented and accessible?
I'd say at the national level, there's ong thing that should be the number 1 policy priority for everybody, and that is to connect with and support local type 1 [diabetes] communities, both people living with type 1 [diabetes] and their health care [caretakers], because I can guarantee they have thought more about this than anybody else. We see them helping to pinpoint where the problem is; they're formidable problem solvers in their own right. Health care systems that work closely with those communities tend to be leading compared to other health care systems. So I think that's that's just a blanket thing like these are smart, committed, insurgent groups—get them involved in solving the problem in your country.
I think internationally there are probably a number of structures that we need to look at establishing to support that national level change. I think a clear strategy would be helpful. I think looking at philanthropic funding models and pooled models will be helpful. We need a consistently and widely used monitoring and evaluation capability so we can see change happening and see failure happening and success happening.
There's a few others. I don't want to get too far over my skis here because that's something we're working right now on with other major players, looking at these things and saying, "What do we need? What are the 5, 6, 7 things we need to establish internationally to support that national level change?" I think that's probably going to unfold in the next 6 to 12 months, so we might have another conversation about that then. I think there are some pretty exciting things coming out of that piece.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More